Physician profile
Hua Ding
NPI 1669545166
$10,840.51
in general payments reported to CMS, 2019-2025
31 companies · $1,808 in 2025
The $1,808 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,956 · 2020: $638 · 2021: $890 · 2022: $1,804 · 2023: $1,782 · 2024: $1,963 · 2025: $1,808.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,541 · Education: $11.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,541.45 |
| Education | $11.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $3,724.22 | 2019-2025 | Vemlidy |
| Astrazeneca Pharmaceuticals Lp | $1,115.44 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Amarin Pharma, INC. | $895.00 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $717.04 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $571.14 | 2021-2024 | Ozempic, Rybelsus |
| Lilly USA, LLC | $455.41 | 2019-2025 | Jardiance, Mounjaro |
| Neurocrine Biosciences, INC. | $390.00 | 2021-2025 | |
| Pfizer INC. | $331.49 | 2019-2025 | |
| Amgen INC. | $322.20 | 2019-2025 | Evenity, Prolia |
| Merck Sharp & Dohme LLC | $264.90 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Teva Pharmaceuticals USA, INC. | $247.11 | 2022-2023 | Austedo Xr |
| Abbvie INC. | $244.39 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $242.63 | 2024-2025 | |
| Glaxosmithkline, LLC. | $211.46 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Ibsa Pharma INC. | $125.00 | 2024 | Licart |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $116.86 | 2019 | |
| Esperion Therapeutics, INC. | $106.60 | 2024-2025 | Nexletol |
| Sanofi Pasteur INC. | $96.00 | 2019-2025 | |
| Exact Sciences Corporation | $95.46 | 2023 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $94.10 | 2024 | Voquezna |
| Intercept Pharmaceuticals, INC. | $62.84 | 2019 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $59.86 | 2022 | |
| Radius Health, INC. | $55.40 | 2019-2020 | |
| Astellas Pharma US INC | $51.11 | 2024 | Veozah |
| Ardelyx, INC. | $48.34 | 2024 | Ibsrela |
| Shield Therapeutics INC | $46.52 | 2023-2024 | Accrufer |
| Kowa Pharmaceuticals America, INC. | $39.22 | 2024 | Zoryve |
| Iridex Corporation | $38.18 | 2019 | |
| Genentech USA, INC. | $37.28 | 2020 | |
| Allergan, INC. | $18.47 | 2019 | |
| Amneal Pharmaceuticals LLC | $16.84 | 2024 | Unithroid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hua Ding listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.